Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials

被引：0
|
作者：
van Vollenhoven, Ronald F. [1 ]
Rubbert-Roth, Andrea [2 ]
Sebba, Anthony [3 ]
Porter-Brown, Benjamin [4 ]
Rowell, Lucy [4 ]
Napalkov, Pavel [5 ]
Smart, Devi [4 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Univ Cologne, D-50931 Cologne, Germany
[3] Univ S Florida, Tampa, FL USA
[4] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[5] Genentech Inc, San Francisco, CA 94080 USA
来源：
ARTHRITIS AND RHEUMATISM | 2013年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2351
引用
收藏
页码：S1005 / S1005
页数：1
相关论文
共 50 条
  • [1] TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND RATES OF MALIGNANCY: RESULTS FROM LONG-TERM EXTENSION CLINICAL TRIALS
    van Vollenhoven, Ronald F.
    Rubbert-Roth, Andrea
    Sebba, Anthony
    Porter-Brown, Benjamin
    Rowell, Lucy
    Napalkov, Pavel
    Smart, Devi
    RHEUMATOLOGY, 2014, 53 : 91 - 92
  • [2] AN INTERIM ANALYSIS OF LONG-TERM EXTENSION TRIALS OF TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    van Vollenhoven, R. F.
    Smolen, J. S.
    Tony, H. P.
    Codding, C.
    Keystone, E. C.
    Woodworth, T.
    Alecock, E.
    Alten, R.
    RHEUMATOLOGY, 2009, 48 : I86 - I87
  • [3] LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS CLINICAL TRIALS
    Taylor, A.
    Nash, P.
    Hall, S.
    Jones, G.
    Youssef, P.
    Porter-Brown, B.
    Thompson, L.
    Genovese, M.
    INTERNAL MEDICINE JOURNAL, 2012, 42 : 14 - 14
  • [4] LONG-TERM SAFETY OF TOCILIZUMAB IN RHEUMATOID ARTHRITIS CLINICAL TRIALS
    Genovese, Mark C.
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan
    Zilberstein, Moshe
    Thompson, Liz
    Van Vollenhoven, Ronald
    RHEUMATOLOGY, 2012, 51 : 75 - 76
  • [5] Long-Term Safety of Tocilizumab in Rheumatoid Arthritis Clinical Trials.
    Genovese, Mark C.
    Sebba, Anthony
    Rubbert-Roth, Andrea
    Scali, Juan
    Zilberstein, Moshe
    Thompson, Liz
    van Vollenhoven, Ronald F.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S866 - S866
  • [6] Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab
    Rubbert-Roth, Andrea
    Sebba, Anthony
    Brockwell, Laura
    Kelman, Ariella
    Porter-Brown, Benjamin
    Pulley, Jennifer
    Napalkov, Pavel
    van Vollenhoven, Ronald F.
    RMD OPEN, 2016, 2 (01):
  • [7] SAFETY AND TOLERABILITY OF TOCILIZUMAB IN LONG-TERM EXTENSION STUDIES OF RHEUMATOID ARTHRITIS
    Nash, P.
    Taylor, A.
    Hall, S.
    Jones, G.
    Youssef, P.
    Genovese, M.
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 17 - 17
  • [8] LONG-TERM TOCILIZUMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE
    Ono, Y.
    Hirano, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1296 - 1296
  • [9] Safety of Tocilizumab in Patients with Rheumatoid Arthritis: An Interim Analysis of Long-Term Extension Trials with a Mean Treatment Duration of 1.5 Years
    Haraoui, Boulos
    van Vollenhoven, Ronald F.
    Smolen, Josef S.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2596 - 2596
  • [10] Safety of tocilizumab in patients with rheumatoid arthritis: An interim analysis of long-term extension trials with a mean treatment duration of 1.5 years
    van Vollenhoven, Ronald F.
    Smolen, Josef
    Tony, Hans P. T.
    Codding, Christine
    Keystone, Ed C.
    Woodworth, Thasia
    Alecock, Emma
    Alten, Ricke
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S784 - S785
12345